To determine the safety and efficacy of propranolol given for 1 year on cardiac function, resting energy expenditure, and body composition in a prospective, randomized, single-center, controlled study in pediatric patients with large burns. Background: Severe burns trigger a hypermetabolic response that persists for up to 2 years postburn. Propranolol given for 1 month postburn blunts this response. Whether propranolol administration for 1 year after injury provides a continued benefit is currently unclear. Methods: One-hundred seventy-nine pediatric patients with more than 30% total body surface area burns were randomized to control (n = 89) or 4 mg/kg/d propranolol (n = 90) for 12 months postburn. Changes in resting energy expenditure, cardiac function, and body composition were measured acutely at 3, 6, 9, and 12 months postburn. Statistical analyses included techniques that adjusted for non-normality, repeated-measures, and regression analyses. P < 0.05 was considered significant. Results: Long-term propranolol treatment significantly reduced the percentage of the predicted heart rate and percentage of the predicted resting energy expenditure, decreased accumulation of central mass and central fat, prevented bone loss, and improved lean body mass accretion. There were very few adverse effects from the dose of propranolol used. Conclusions: Propranolol treatment for 12 months after thermal injury, ameliorates the hyperdynamic, hypermetabolic, hypercatabolic, and osteopenic responses in pediatric patients. This study is registered at clinicaltrials.gov: NCT00675714.
tein catabolism, resulting in loss of muscle mass and a subsequent increase in the risk of organ failure or death. 1 These prolonged hypermetabolic changes can last for at least 1 to 2 years after the injury. 2, 3 Catecholamines, which are elevated for 2 years postburn, are primary mediators of the hypermetabolic response. 4, 5 Catecholamines potentiate cardiovascular activity such as increased myocardial oxygen consumption, local myocardial hypoxia, tachycardia, and increased myocardial contractility. 6 Elevated levels of catecholamines have further been associated with cardiotoxicity, as evidenced by myocardial necrosis and myocarditis. 7 Propagation of catecholamine signaling is mainly through the β-adrenergic receptors.
Propranolol, a nonselective β-adrenergic receptor antagonist, mitigates the actions of plasma catecholamines and significantly reduces the hyperdynamic and hypermetabolic state in patients with acute burn injury. 5 Administration of this drug for 2 weeks to decrease admission heart rate by 15% augments net protein balance in muscle, decreasing loss of lean mass and lowering resting energy expenditure. 8 Cardiac function is improved by propranolol administration because of reductions in cardiac work as measured by the rate pressure product [rate pressure product = heart rate × mean arterial pressure]. 9 The beneficial effects of β-blockade are not, however, limited to patients with burn injury, as patients undergoing major elective surgery experience fewer cardiac complications and overall mortality when treated with β-blocking agents. 10 Although propranolol seems to be beneficial in critical care, concerns remain regarding whether propranolol will increase morbidity in patients with burn injury by blunting the stress and hyperdynamic responses. Animal studies suggest that propranolol may decrease some immune functions and is detrimental during infectious episodes or septicemia. 11 Deleterious effects on immune function or inflammation were not noted in a study of children with severe burn injury given propranolol acutely. 12 Moreover, a large randomized study of adult surgical patients who had atherosclerotic disease and were undergoing noncardiac surgery suggests that β-blockade with metoprolol is associated with increased mortality. 13 This prospective, randomized, single-center, controlled study was conducted to determine whether long-term propranolol administration improves cardiac function, resting energy expenditure, and body composition. This study presents an interim analysis of the aforementioned parameters including adverse events. Study patients, 0.3 to 18 years of age at the time of injury, had more than 30% total body surface area burns and required 1 or more surgical interventions. Patients were excluded from study participation if they met one of the following criteria: burn injury deemed so severe as to be futile to treat; anoxic brain injury; the presence of preexisting conditions such as Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome; 5-year history of malignancy, severe diabetes, or asthma; or an inability to obtain informed consent. Propranolol treatment was started within 3 ± 2 days following admission. Patients received doses of propranolol intended to lower their heart rate by 15% (mean dose, 4 mg/kg/d). When bradycardia occurred, a single dose of propranolol was held and administration recommenced after 16 hours with one half of the original dose. The dose was then escalated back to the 4 mg/kg/d dose over the following 48 hours. Assessments were performed at admission, during the hospital stay, at discharge, and at 3, 6, 9, and 12 months after injury. Data from patients withdrawing from the study were included in the analysis up to the time of withdrawal. This study was part of a larger trial (www.clinicaltrials.gov, NCT00675714) designed to determine burn outcomes after administration of anabolic agents including oxandrolone, growth hormone, and insulin. Legal guardians provided consent by signing a written informed consent form approved by the institutional review board of the University of Texas Medical Branch (Galveston, TX). Assent was obtained from children older than 7 years before study enrollment.
Standard Burn Care
Fluid resuscitation was given according to the Galveston formula (a total of 5000 mL/m 2 total body surface area burned + 2000 mL/m 2 total body surface area lactated Ringer solution given during the first 24 hours). For all patients, burn wound excision and placement of autograft or allograft was performed within 48 hours of admission. Following 4 days of bed rest, patients ambulated every day until the next surgery. Excision and grafting procedures were repeated every 6 to 7 days until all burned sites were 95% healed.
Patients were fed Vivonex TEN enteral nutrition (6% fat, 15% protein, 82% carbohydrate) via a nasoduodenal or nasogastric tube. Initially, intake was determined using the formula 1500 kcal/m 2 total body surface area + 1500 kcal/m 2 total body surface area burned. After the first week of hospitalization and throughout the remainder of acute hospitalization, this intake was modified to 1.4 times the weekly measured resting energy expenditure (see Indirect Calorimetry for more details). Nutritional status was monitored in all hospitalized patients by measuring levels of retinol-binding protein, prealbumin, and albumin. After discharge from the hospital, patients' diets were supplemented 3 times per day with Boost (Nestle Health Care Nutrition, Nestlé S.A., Vevey, Switzerland; 41 g of carbohydrate, 10 g of protein, and 4 g of fat). Supplementation continued until the nutritionist confirmed that the regular diet met the patient's caloric requirements of 1.4 times the resting energy expenditure. Dietary intake was determined through interviews with caretakers, which were conducted daily when patients visited the tub room, weekly while residing close to the hospital, and at long-term clinical follow-up visits by recall questionnaires.
Patient Characteristics
At admission, patient demographics (eg, age and sex) and injury characteristics (eg, burn depth and size) were recorded. Burn size was determined using age-appropriate diagrams. 14 During the remainder of hospitalization, mortality, morbidity, sepsis, and inhalation injury were also documented. 15 Fiber-optic bronchoscopy was performed 24 hours after admission to identify inhalation injury, which was confirmed by the presence of mucosal necrosis, charring, soot, inflammation, or airway edema.
Cardiac and Blood Pressure Measurements
Resting heart rates and blood pressures were measured by continuous arterial monitoring or noninvasive cuff measurements. Recordings were made continuously during acute hospitalization and at each follow-up visit. Patients and families were issued blood pressure cuffs, taught how to use them, and asked to measure and record heart rate and blood pressure 4 times per day. They were instructed to call a nurse or physician if the patient's heart rate was less than 60 beats per minute or blood pressure was less than normal for the patient's age. Heart rate values were compared with accepted normograms for age-matched, healthy children with no burn injury and were analyzed as percentages of predicted heart rate to control for age-related differences. 16, 17 The percentage of predicted heart rate was calculated by dividing the actual heart rate by the age-adjusted normogram. The rate pressure product was calculated as the product of the mean arterial pressure and heart rate. 17 Heart rate and blood pressure data collected by the parents were reviewed by a pediatrician at least every week initially and then less often as indicated. The propranolol dose was titrated up to provide systolic blood pressure and pulse within 15% of the mean values of the normal population of that age. The parameters to be met for receiving the next dose of medication were a systolic blood pressure of 90 mm Hg for teens down to 80 mm Hg for younger children and a heart rate ranging from 70 beats per minute for teenagers up to 90 beats per minute for younger children. If the parameter was not met at the time of the next dose, the dose was not given until the time of the following dose. If several doses were not given in a week because the parameters were not met, then the dose was adjusted to a lower level so that the parameters were being met.
Indirect Calorimetry
A Sensor-Medics Vmax 29 metabolic cart (Yorba Linda, CA) was used to measure resting energy expenditure at weekly intervals during the acute hospital stay. Measurements were obtained from resting patients between 12 AM and 5 AM. Inspired and expired gas analysis was performed every minute. When CO 2 production and O 2 consumption reached a steady state and were maintained for 5 minutes, the values were recorded. Measured values were compared with normal values, which were predicted using the body mass index and the Harris-Benedict equation. 14, 18, 19 Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Body Composition
Central mass, central fat, peripheral lean body mass, total bone mineral content, and total lumbar bone mineral content were measured by dual-energy x-ray absorptiometry (QDR-4500W Hologic, Waltham, MA). Systematic deviations were minimized by performing daily calibrations with a spinal phantom in the single-beam, lateral, and anteroposterior modes. Individual pixels were calibrated using a tissue bar phantom to correctly identify air, bone, fat, or lean mass. 20 Feedings and intravenous fluids were discontinued before the examination and reinitiated afterward. Results were expressed as the percentage change from patient baseline values within 3 ± 2 weeks postburn. Bone loss was determined by calculating the percentage change from baseline at each time point and stratifying patients on the basis of a more than 5% loss in 2 parameters obtained from dualenergy x-ray absorptiometry measurements: total body bone mineral content minus head per total body mass and total lumbar bone mineral content. The proportion of propranolol and control patients in each stratum was determined, and the likelihood [odds ratios ± 95% confidence interval] of presenting a clinically significant bone loss of at least 5% in both of these parameters was estimated.
Measurement of Hormones
Blood and urine were collected at admission, during acute hospitalization, and at follow-up visits. Blood was collected in serumseparator tubes and centrifuged at 1320 revolutions per minute for 10 minutes. The resulting serum was stored at −80 • C until further analysis. Serum levels of parathyroid hormone, insulin-like growth factor 1, insulin-like growth factor binding protein 3, osteocalcin, testosterone, albumin, and total protein were determined using high-performance liquid chromatography and enzyme-linked-immunosorbent assay, as described elsewhere. [18] [19] [20] Urinary catecholamine levels were determined as previously described. [18] [19] [20] 
Statistical Analysis
The data distribution was evaluated using the Kolmogorov-Smirnov normality test and QQ plots. Two-sided equal-variance t tests were used to compare normally distributed continuous data. Two-sided Wilcoxon exact tests were used to compare non-normally distributed data. Normally distributed data are presented as the means ± standard deviation or standard error of the mean. Frequency data are expressed as percentages or counts. All trends in the data were estimated using analysis of covariance models, which adjusted the posttreatment measurement with the baseline measurement as a covariate and are presented as the expected value ± standard error of the mean. Testing of differences between control and propranolol were done using standard t tests on the coefficients of treatment effect within each of the models. Each time point was modeled and tested separately. To control the overall family-wise error rate across time, we used a step-down procedure based on the permutation distribution. 21 To stabilize the variance and keep the data distribution approximately normal, we transformed data, when necessary, using the Box-Cox family of transformations. Confidence intervals for odds ratios were calculated on the basis of Fisher exact test calculations. A permutation test corrected by a step-down procedure was used to correct for elevated overall type I error rates across time. 21 SAS (version 9.2) and R (version 13.2) were used for data analysis and hypothesis testing. Error rates (overall and individual P values) less than 0.05 were accepted as significant.
RESULTS

Patient Disposition and Demographics
Of the 179 patients enrolled in this study, 5 were lost to followup (control, n = 2; propranolol, n = 3) and 5 withdrew from study participation (control, n = 3; propranolol, n = 2). Demographics did not differ significantly between groups (Table 1) . Two thirds of the patients were male, which is typical of the overall patient representation at our institution. The severity of the injury was comparable in both groups (as assessed by the percentage of total body surface area burned and percent of third-degree burned). One third of the patients in each group had an inhalation injury (P = 0.49). The length of hospital stay was approximately 1 / 2 day per percentage of total body surface area burned. Mortality was low, with no significant difference between the control and the propranolol groups (P = 0.72); the deaths were due to sepsis (n = 6). Assessments of infections, pneumonias, and acute respiratory distress syndrome demonstrated no significant differences between groups. Nutritional status on admission to the burn unit did not differ between groups. Dietary intake was comparable between the groups throughout the 12-month study.
Cardiac Function
To evaluate the efficacy of β-blockade with propranolol on cardiac function, we calculated the percentage of predicted heart rate 16, 17 ( Table 2 ). Measurements were recorded continuously during hospitalization and at each follow-up visit. Burn-related elevation in heart rate was approximately 1.7-fold above normal for age in both groups at the time of admission (control, 169 ± 34% predicted vs propranolol, 163 ± 33% predicted; P = 0.19). The rate pressure product (mean arterial pressure × heart rate) was obtained as a correlate of myocardial oxygen consumption. 17 The rate pressure product increased by approximately 1.6-fold in both groups (control 11,009 ± 280 beats per minute vs propranolol 11,435±304 beats per minute × mm Hg, P = 0.66). Propranolol significantly lowered the percentage of the predicted heart rate ( Fig. 2A) , an effect that persisted up to 1 year postburn (119 ± 2% vs 110 ± 2%, P = 0.01). Propranolol reduced the percentage of the predicted heart rate at 1 week postburn by approximately 15%. Similarly, the rate pressure product was significantly lower in the propranolol group than in the control group between 2 weeks and 6 months postburn (by ∼15%) (Fig. 2B ). Arterial pressure was monitored by mean arterial pressure recordings as a continuous variable and, alternatively, by comparing the probabilities of developing hypotension (mean arterial pressure <65 mm Hg) to determine whether propranolol adversely affects arterial pressure. Propranololtreated patients showed subtle decreases in mean arterial pressure as compared with control patients at 2 weeks, 4 weeks, and 2 months. However, these decreases did not reach significance after adjusting for multiple testing, nor did they represent an increased number of instances of hypotension (mean arterial pressure <65 mm Hg, n = 0).
Hypermetabolism
The percentage of predicted resting energy expenditure changed over time (Fig. 2C ). All patients were hypermetabolic by the initial study period, as seen by comparison with the basal metabolic rate predicted by the Harris-Benedict equation. 22, 23 In both control and propranolol groups, the percentage of predicted resting energy expenditure peaked at 140% and 120%, respectively. Both groups remained hypermetabolic throughout the 12-month time frame, as determined by the elevated percentage predicted resting energy expenditure measurements. The percentage of predicted resting energy expenditure significantly decreased beginning with the acute studies and continuing throughout 6, 9, and 12 months postburn. This decrease was more pronounced in the propranolol group than in the control group between 2 weeks and 6 months postburn. were measured by dual-energy x-ray absorptiometry (Fig. 3 ). In both groups, total body mass increased between baseline and 12 months postburn ( Table 2 ). Despite both groups having similar nutritional intake, central mass accretion was significantly higher in the control group, whereas there was a 17% decrement in central mass as early as 3 months postburn after propranolol administration. These differences between the groups were significant throughout 12 months postburn (Fig. 3A) . Central fat mass was significantly lower in the propranolol group than in the control group, reaching a maximal decrease of 23% at 12 months postburn (Fig. 3B ). An 11% increase in peripheral lean body mass was seen in the propranolol group when compared with the control group at 6 months postburn (Fig. 3C ). Approximately 70% of control and 50% of propranolol-treated patients lost more than 5% of total bone mineral content/total body mass by 6 months postburn (P = 0.01). Propranolol decreased the likelihood of total bone mineral content/total body mass loss at 6 months (odds ratio = 0.5; 95% confidence interval, 0.25-0.75) when compared with control; this effect remained significant throughout the rest of the study period ( Fig. 3D , Table 3 ).
The propranolol group also had a lower likelihood of experiencing a 5% loss of total lumbar bone mineral content or more than the control group during the study duration (Fig. 3E) . Propranolol significantly preserved lumbar bone mineral content at 3, 6, 9, and 12 months (P = 0.02).
Adverse Events
Incidences of hypotension, bradycardia, hypoglycemia, cardiac arrhythmia, respiratory arrest, and death were recorded. In the control group, there were 5 deaths. In the propranolol group, there were no occurrences of hypotension with few incidences of bradycardia (n = 2), hypoglycemia (n = 1), cardiac arrhythmia (n = 1), respiratory compromise (n = 2), and death (n = 4). In all cases of adverse events, propranolol treatment was halted and reinitiated according to the standard operating procedure delineated in the Methods section. Autopsies of 5 control patients and 4 propranolol-treated patients revealed the cause of death to be sepsis in all cases.
DISCUSSION
Three hundred patients in each group had been planned for this large, randomized, single-center controlled study, which was designed to test the efficacy of propranolol in children with more than 30% total body surface area burns when given at an approximate dose of 4 mg/kg/d from 96 hours postburn until 1 year later. An interim analysis was planned after enrollment of 90 patients per group. In this study, the 4-mg/kg/d dose of propranolol was extremely well tolerated in the pediatric age group used, with few episodes of bradycardia, hypoglycemia, morbidity, or major adverse effects related to the use of this drug.
The primary aim of the study was to determine whether this dose of propranolol decreased heart rate by approximately 15%. For the duration of drug administration, there was a persistent decrease in heart rate. Although the rate pressure product was decreased by approximately 15% at 4 weeks postburn, all patients, whether in the control or propranolol group, still exhibited massive tachycardia of 120% to 140% of the predicted normal for 1 to 3 months after injury. Heart rate then decreased to 110% at 6 months postinjury with propranolol administration. Larger doses of propranolol could potentially decrease heart rate and cardiac work even more than demonstrated here, because very few episodes of bradycardia and no significant decreases in blood pressure were seen with the 4-mg/kg/d dose. Elevations in cardiac work caused by persistent tachycardia could then be reduced even further. Patients need to be studied well into adulthood to see whether these prolonged episodes of tachycardia and increased cardiac work have long-term effects on cardiovascular morbidity as well as to determine whether decreasing heart rate with propranolol reduces this morbidity.
Resting energy expenditure was a secondary end point of this study, and the administration of propranolol did decrease resting energy expenditure by 20% during the first 6 months after injury. Understanding whether a larger dose would have a greater affect and whether long-term benefits of this diminution of resting energy expenditure in this patient population will require following children to full growth and examining strength, growth, height and weight velocities, final stature, and their return to work and school. Another end point of the study was central mass. Propranolol was found to decrease accrual of central mass by 15% at 3 months postburn and for as long as the drug was being administered relative to control patients, who exhibited a 25% increase in the percentage change of central mass from baseline. In the propranolol group, central mass remained at or below baseline. Central mass is composed of organs (liver, spleen, kidney) and mesenteric fat. Dual-energy x-ray absorptiometry revealed that, in the propranolol group, truncal fat was reduced by approximately 15%, with truncal fat remaining at or below or baseline levels throughout the hospital course. In contrast, controls exhibited a 20% increase from baseline over 1 year after injury.
Taken together, these findings indicate that propranolol decreases the central deposition of fat, a finding that is in keeping with the previous studies by Wolf and Herndon showing that propranolol decreases mesenteric blood flow 24 and reduces peripheral lipolysis. 25 Burn-induced lipolysis typically results in the hydrolysis of triglycerides into free fatty acids, which are then released into the circulation and deposited in tissues or vital organs. A reduction in mesenteric fat may therefore be accompanied by fatty liver and a subsequent increase in liver size, and this may result in liver dysfunction. Steatosis of vital organs aside, lipolysis and free fatty acids contribute to postburn morbidity and mortality by mediating insulin resistance. 26 Insulin-stimulated glucose uptake is impaired by free fatty acids and triglycerides, 27, 28 with insulin resistance occurring as a direct consequence of the inhibition of glucose transportation activity. 29 Recent evidence suggests a strong relationship between fat and glucose metabolism. 30 In addition, catecholamines increase lipolysis, further stimulating insulin resistance.
Jin et al 31 have suggested that chronic elevation of interleukin-6 and inflammatory mediators results in organ hypertrophy after a thermal injury. This study has also suggested that the use of βblocking agents may decrease the inflammatory response by decreasing levels of interleukin-6, monocyte chemotactic protein-1, and other cytokines. 12 Another secondary end point of the study was peripheral lean body mass, which showed a 10% improvement in the propranolol group compared with the control group. This finding is in keeping with previous studies showing an improvement in protein to find out whether it was protein synthesis or protein degradation. 8 In this study, the beneficial effects of propranolol could also be extended to bone. In previous animal experiments, propranolol was shown to be beneficial in the partial preservation against postovariectomy bone loss. 32 It has been previously shown that propranolol reduces bone mineral loss after burns. 33 The direct or indirect effects that β-blocking agents provide for bone have yet to be elucidated. This study shows that the odds ratio for more than 5% loss of total bone mineral content is reduced by propranolol. Improvement in bone strength may indirectly improve lean body mass. In consideration of the changes in bone mass and density, bone growth spurts were examined. The number of individuals with growth spurts in each group was similar. Data predict that continuation of this study to meet the full sample size of 300 patients per group will provide sufficient power to determine whether propranolol affects infections and whether there will be a long-term effect on growth (as seen by height and weight percentiles in this patient population over time).
In this study, all patients who were older than 7 years were offered the opportunity to participate in a 3-month exercise program in which children exercised 5 days a week at 75% of their individual maximum oxygen consumption ( . V o 2 max) and used progressive resistance exercise, lifting 8 to 12 times their maximum capacity for 3 sets, 3 times weekly. An equal number of individuals in each group (control or propranolol) participated in the exercise program. Patients who did not participate in the exercise program were exercise tested and given physical and occupational therapy routines that involved exercise. An equivalent number of patients declined exercise therapy in each group. All patients were tested when they returned to the clinic at 6, 9, and 12 months postburn. There were no differences in habitual physical activity reported by the patient's parents or evaluated by exercise testing capabilities at discharge or at the 6-or 12-month intervals.
Nutrition was controlled because it affects all of the variables that were studied. As described in the Methods section, all patients admitted to the hospital were administered enteral nutrition via continuous drip 1500 kcal/m 2 total body surface area + 1500 kcal/m 2 total body surface area burned. Patients in both cohorts tolerated the nutritional diet equally well. Upon discharge, each patient was advised by a dietician to eat 1.4 to 1.6 times their resting energy expenditure with detailed diary training performed on at least 2 different occasions for all patients in the study. Dietary recall was obtained when patients returned at 6-and 12-month intervals. No differences in dietary intake between the 2 groups could be detected, probably due to the large number of individuals from similar social, economic, and cultural backgrounds.
The patients enrolled in this study were young, with an average age of 7 ± 5 years in each group. Four of the patients underwent menarche (2 in each group). Although the number of males allocated to propranolol was greater (74% vs 63%, propranolol and control, respectively), there were no statistically significant sex differences between the 2 groups. Thus, it is unlikely that this is a type 2 error, as this was a randomized study. Larger numbers will be enrolled in outcome studies to validate this assumption.
The initial analyses of patients administered short-term or long-term propranolol have shown that there is no effect on acute stress disorder or posttraumatic stress disorder. Analyses of larger groups at 5 and 10 years postburn will be conducted to determine whether propranolol impacts psychological outcomes such as those measured by the Shriners outcome instruments. Larger numbers and longer follow-up will be required to achieve significance, given the limits of these measures.
Future studies will investigate cardiopulmonary and muscle endurance by assessing patients' aerobic capacity as well as longterm outcomes of these individuals by looking at the time to return to school, acute distress disorder, posttraumatic stress disorder, and anxiety over all, as examined by scaled psychological tests.
In conclusion, analysis of long-term administration of propranolol in children with more than 30% total body surface area burns indicates that this treatment is safe and markedly decreases heart rate and cardiac work. It also shows that this treatment decreases central body mass, reduces truncal fat, and improves lean body mass and bone mineral density. This study suggests that a larger study population will show long-term health benefits in terms of growth, cardiac health, and improvement of the metabolic syndrome.
DISCUSSANTS
B. Pruitt, Jr (San Antonio, TX): Over the past 4 decades, Dr Herndon and his colleagues have characterized the metabolic responses to severe injury and now present these intriguing data, suggesting that these responses can be safely modified to the patient's benefit.
You note that propranolol reduced central body mass and truncal fat. Were those changes accompanied by alteration of fat as an energy source? Specifically, did you calculate the respiratory quotient (RQ) when you measured resting energy expenditure, and was it lower in the propranolol-treated patients? If it was not, by what mechanism do you propose propranolol decreases central fat accumulation?
Because lean body mass is strongly influenced by exercise, how comparable was the physical activity in the 2 groups, and was there any difference between males and females in lean body mass accretion?
In that same vein, was there a difference in the number of children in the 2 groups who participated in the special on-site exercise programs that you have reported to be so beneficial?
You note that after discharge from the hospital, the patients received dietary supplements until the "nutritionist confirmed that the regular diet met the caloric goal." Was the duration of such support and such supplementation comparable in the 2 groups?
Recently, you and your colleagues reported that the adipose tissue transcriptome is markedly altered after burn injury, with an upregulation of genes involved in inflammation pathways. Were these gene alterations reduced by propranolol? And, if so, are these patients more susceptible to infection?
Also, if 4 mg/kg/d evokes all of these good effects, would 8 mg/kg/d be twice as good?
Finally, if we are to apply this treatment to other patients, should the dose be proportional to the severity of injury as defined by some score or perhaps, more specifically, the magnitude of hypermetabolism?
The possible application of these findings to other surgical populations makes this an article of potentially great importance.
Response from D.N. Herndon:
We performed RQs, and they do go along with the results that we demonstrated. Lipolysis is decreased by propranolol. We intend to do studies with stable isotopically labeled palmitate to confirm the mechanism, but peripheral lipolysis is prevented and central deposition of fat in the liver is diminished. There is a decrease in blood flow to the liver and a decrease in central deposition of fat, which is a presumed mechanism for that.
Physical activity is similar in both cases. We do advocate for an exercise program in which patients exercise aerobically 3 days a week, to 75% . V o 2 max, and 2 days a week to 3 repetitions of 75% maximum of their lifting and pushing capabilities. There were equal numbers of patients who participated in this activity in both groups. Propranolol seems to have improved aerobic capacity, and we will be analyzing these data in more detail in the future.
The dietary supplementation in these individuals was equal between the groups. We keep patients in the hospital for 2 months after discharge, and they are seen by a dietitian on a daily basis, with dietary recall 5 days per week and supplementation administered to meet 1.4 times the resting energy expenditure requirements.
These supplementations are continued in those patients who need it after the first 2 months. Dietary recall was performed at 3, 6, 9, and 12 months in all cases. There were no differences in dietary intake that were recordable for the 2 groups.
Adipose tissue transcriptome was examined in these individuals, and, in fact, there is a marked upregulation of inflammation in fat. Fat tissues seem to be highly active after burn injury, perhaps secreting cytokines and serving as the source of lipolysis.
The changes in the transcriptome in the fat are very similar to those that I showed briefly in muscle, with a decrease in βand α-adrenergic signaling transduction pathways, cyclic A and P transduction pathways, and leptin.
As for the inflammatory responses and increases and decreases, infection may or may not be present in this group, and this will be studied in the full trial, where the power to distinguish infections will be achieved.
The dose of propranolol should probably be more than 4 mg/kg/d, which is a very high dose and one that would perhaps strike fear into a normal surgeon's heart; but in fact, we started with this beginning dose and we think we may be able to push it even higher. We were able to decrease heart rate by only 15%, yet these patients remain massively tachycardic throughout the first year postinjury. Cardiac work could be decreased more by increasing the dose, and we will do that according to injury and according to metabolic response in future studies.
W.G. Cioffi (Providence, RI):
Almost 200 patients were randomized in this 1-year propranolol trial, with laboratory, metabolic, and body composition studies performed. The treatment was safe, with few untoward effects, and did show significant effects on reducing cardiac work and resting energy expenditure.
Your results are statistically significant, but are they clinically relevant? You have more than 3 decades of burn experience. Do you know if severely burned children truly are at risk later in life for cardiac events and does propranolol supplementation for 1 year reduce this risk?
More important are the metabolic effects that you measured in your patients. Do the treated children really show improved muscle strength and exercise tolerance?
In order for this to really make a difference, these kids should show increased muscle mass, increased muscle strength, and exercise tolerance.
Response from D.N. Herndon: How propranolol will decrease future cardiac events in these patients remains to be determined by following up with them for 5 and 10 years and conducting studies with a larger number of patients.
Similarly, strength and aerobic capacity were improved in patients receiving propranolol, but determining effects on growth, stature and whether these children attain full growth, which their predecessors have not, will require 5-and 10-year follow-up and 150 to 300 persons in each group, and we intend to do this.
DISCUSSANTS
A. Meyer (Chapel Hill, NC): Our sample comprised a single patient (n = 1) who sustained a burn injury as a child and had an identical twin with no burn injury. We saw the significant difference in growth.
Given the studies that you are doing, are you considering using echocardiography to measure ventricular wall thickness, chamber volume, and ejection fraction to see if any of the parameters of long-term effects of the propranolol are helpful in those patients by changing these characteristics in your patients with burn injury?
Response from D.N. Herndon: That is an excellent suggestion, and we do intend to use transesophageal echocardiography to measure the parameters you suggest. Preliminary data indicate that there are salutary effects. We will follow that up and report back to you personally and publicly.
S. Dudrick (Waterbury, CT): I would just like to ask what your thoughts are about the intangible explanation of why we do better, at least clinically, and yet the outcomes, meaning the ultimate outcome, death or survival, do not reward us. Are there any other things that you have measured or can measure to indicate that the expenditure of so much effort and resources on your part and that of your team and on ours is merited by something better for the patient? I know it is more of a philosophical, ethical question than an objective one, but it is one that has been bugging me for more than 45 years. The critics say that you are not really doing any good and I do not mean to imply that at all. I am entirely in favor of what David has done, and in awe of the results. I thank him from the bottom of my heart.
We hope that by giving propranolol to a very large number of patients over time, we will decrease stress and anxiety. We hope to decrease acute stress disorder or posttraumatic stress disorder. We hope that this agent will improve strength and will allow patients to return to work and school earlier.
We have to look at long-term outcomes to see, as Dr Cioffi indicated, whether giving this drug really will make a difference.
Importantly, this patient population is not cured when they go home. They are massively ill for a very, very long time. Many of our trauma patients and many of our surgical patients are weakened. They suffer ravages that persist for months and years after we work with them and on them. We need to treat these ravages with agents, such as propranolol, pain medicines, anti-anxiety medicines, and moodaltering medicines, to make their lives better.
I think we should be committed to improving long-term outcomes and not just focusing on physiological and metabolic effects.
